Seoul, Korea – 26/04/2024 – (SeaPRwire) – Dr. Eric A. Johnson and Professor Dirk Dressler, internationally famend botulinum toxin specialists, visited South Korea in March this 12 months to affix WizMedi Bio’s new botulinum toxin improvement challenge. Their involvement is anticipated to profoundly increase product improvement and registration processes.
The long-standing collaboration between Dr. Johnson and Professor Dressler has formed the worldwide botulinum toxin panorama over the previous many years. Dr. Johnson, a retired professor of bacteriology on the College of Wisconsin-Madison within the US, has devoted over 4 many years to botulinum toxin analysis, authoring over 200 publications and based 3 botulinum toxin firms. His outstanding contributions led to the event of the primary botulinum toxin drug.
Professor Dressler, the pinnacle of the Motion Problems Part at Hannover Medical Faculty in Germany, has been on the forefront of each translational botulinum toxin analysis and the event of all vital medical purposes, together with dystonia, spasticity, migraine, hyperhidrosis, and aesthetic indications. Having launched a lot of the main botulinum toxin medication to the worldwide markets, he’s a extremely sought-after guide to the botulinum toxin business.
WizMedi Bio lately introduced the acquisition of the unique rights to the newly developed and patented botulinum toxin sort A6 pressure from the Wisconsin Alumni Analysis Basis(WARF), a subsidiary of the College of Wisconsin.
Associated hyperlink:
Throughout their go to to Korea, Dr. Johnson and Professor Dressler visited BNC Korea’s cutting-edge manufacturing and analysis services, solidifying the optimistic outlook for the challenge’s success. BNC Korea and WizMedi Bio fashioned a strategic partnership in 2023 to analysis and develop new botulinum toxin merchandise.
Dr. Johnson expressed his enthusiasm by saying: ” I’m excited concerning the novelty of A6 botulinum toxin and its potential as a brand new drug within the rising botulinum discipline. My go to to WizMedi Bio and their professionalism has solely strengthened my confidence on this challenge.”
Dr. Yonghun Choi, the CEO of WizMedi Bio, stated: “The two experts are already mythical figures in the botulinum toxin arena, and it is an absolute delight for us to work with both of them simultaneously. We look forward to working with them to bring our new potent A6 toxin to the market as soon as possible.”
Social Hyperlinks
Twitter: https://twitter.com/WIZMEDIKR
Media Contact
Firm: Wizmedi Co., Ltd.
Contact: Media Crew
Electronic mail: advertising@wizmedi.kr
Web site: https://wizmedi.kr
SOURCE: Wizmedi Co., Ltd.
The article is offered by a third-party content material supplier. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith.
Sectors: Prime Story, Company Information
SeaPRwire offers actual time press launch distribution for firms and organizations to six,500+ media retailers & 3.5 million skilled desktops in 90 areas. It distributes press releases in numerous languages, together with: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi …
